Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.045413 USD
−37.43 M USD
58.22 M USD
344.01 M
About Ocumension Therapeutics
Sector
Industry
CEO
Ye Liu
Website
Headquarters
Suzhou
Founded
2018
ISIN
KYG674111011
FIGI
BBG011KF7155
Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company was founded in 2017 and is headquartered in Suzhou, China.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange OCUMENSION THERAPEUTICS stocks are traded under the ticker OCUTF.
We've gathered analysts' opinions on OCUMENSION THERAPEUTICS future price: according to them, OCUTF price has a max estimate of 1.58 USD and a min estimate of 1.30 USD. Watch OCUTF chart and read a more detailed OCUMENSION THERAPEUTICS stock forecast: see what analysts think of OCUMENSION THERAPEUTICS and suggest that you do with its stocks.
Yes, you can track OCUMENSION THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
OCUMENSION THERAPEUTICS is going to release the next earnings report on Mar 20, 2026. Keep track of upcoming events with our Earnings Calendar.
OCUTF earnings for the last half-year are −0.02 USD per share, whereas the estimation was −0.02 USD, resulting in a −41.67% surprise. The estimated earnings for the next half-year are 0.00 USD per share. See more details about OCUMENSION THERAPEUTICS earnings.
OCUMENSION THERAPEUTICS revenue for the last half-year amounts to 41.03 M USD, despite the estimated figure of 44.33 M USD. In the next half-year revenue is expected to reach 71.57 M USD.
OCUTF net income for the last half-year is −18.10 M USD, while the previous report showed −16.32 M USD of net income which accounts for −10.89% change. Track more OCUMENSION THERAPEUTICS financial stats to get the full picture.
No, OCUTF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 27, 2025, the company has 489 employees. See our rating of the largest employees — is OCUMENSION THERAPEUTICS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OCUMENSION THERAPEUTICS EBITDA is −21.57 M USD, and current EBITDA margin is −52.20%. See more stats in OCUMENSION THERAPEUTICS financial statements.
Like other stocks, OCUTF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OCUMENSION THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.